Krishna Institute of Medical Sciences Ltd Upgraded to Sell on Financial and Technical Shifts

Financial Quality Assessment: A Decline Amidst Revenue Growth

The financial quality of KIMS remains under pressure, with the company’s latest quarterly results for December 2025 revealing a very negative financial trend. The financial trend score deteriorated further to -23 from -19 over the past three months, signalling worsening fundamentals. While net sales reached a record high of ₹997.70 crore, profitability metrics tell a different story.

Profit after tax (PAT) for the quarter plunged by 34.8% compared to the previous four-quarter average, settling at ₹53.40 crore. This decline is compounded by a return on capital employed (ROCE) at a low 10.97% for the half-year, the lowest in recent periods, indicating suboptimal utilisation of capital. The company’s debt-equity ratio has climbed to 1.40 times, the highest recorded, raising concerns about leverage and financial risk.

Operating profit to interest coverage ratio has also dropped to a precarious 3.50 times, while interest expenses surged to ₹56.80 crore, the highest quarterly figure. Earnings per share (EPS) fell to ₹1.34, marking the lowest quarterly EPS in recent history. These metrics collectively highlight deteriorating profitability and increasing financial strain despite top-line growth.

Valuation and Market Capitalisation Considerations

From a valuation standpoint, KIMS is currently graded 3 on market capitalisation, reflecting its mid-sized stature within the hospital sector. The stock trades at ₹683.45, up 5.17% on the day, with a 52-week high of ₹798.00 and a low of ₹474.55. Despite the recent price appreciation, the company’s valuation remains expensive relative to its returns, with an enterprise value to capital employed ratio of 5.7 times.

ROCE of 10.6% juxtaposed with this valuation suggests the stock is priced at a premium to its capital efficiency. However, the stock is trading at a discount compared to its peers’ historical averages, offering some relative value. Over the past year, KIMS has delivered a 13.91% return, outperforming the Sensex’s 10.41% gain, though profits have declined by 16.1% in the same period, indicating a disconnect between price performance and earnings trajectory.

Financial Trend Shift: From Negative to Very Negative

The financial trend downgrade to very negative is primarily driven by the company’s deteriorating profitability and rising debt levels. The consecutive negative quarterly results over the last three quarters have eroded investor confidence. Operating profit growth has been modest at an annual rate of 5.84% over the past five years, which is insufficient to offset the recent earnings decline.

Despite these headwinds, KIMS demonstrates some operational strengths. Management efficiency remains high, with a reported ROCE of 22.32% in certain assessments, suggesting pockets of effective capital deployment. Additionally, the company maintains a healthy average EBIT to interest coverage ratio of 12.39, indicating a reasonable ability to service debt despite rising interest expenses.

Technical Analysis: Mild Improvement but Bearish Bias Persists

Technically, KIMS has seen its trend improve from bearish to mildly bearish, reflecting a cautious optimism among traders. Weekly and monthly MACD indicators remain bearish and mildly bearish respectively, while the Relative Strength Index (RSI) shows no clear signal on both weekly and monthly charts. Bollinger Bands, however, indicate bullish momentum on weekly and monthly timeframes, suggesting potential price support.

Moving averages on the daily chart are mildly bearish, and the KST (Know Sure Thing) oscillator aligns with a bearish weekly and mildly bearish monthly stance. Dow Theory signals are mixed, with weekly readings mildly bullish but monthly trends mildly bearish. On-balance volume (OBV) also remains mildly bearish across weekly and monthly periods, indicating subdued buying pressure.

These mixed technical signals have contributed to the upgrade from Strong Sell to Sell, reflecting a less pessimistic outlook but still cautioning investors about potential volatility and downside risks.

Comparative Performance and Institutional Confidence

Over various time horizons, KIMS has outperformed the Sensex benchmark significantly. The stock returned 12.11% over the past week versus Sensex’s 0.50%, 10.22% over the last month compared to 0.79%, and 12.58% year-to-date against a negative 1.16% for the Sensex. Over one year, the stock gained 13.91% while the Sensex rose 10.41%, and over three years, KIMS surged 132.67% compared to Sensex’s 38.81%.

Institutional investors hold a substantial 47.04% stake in the company, signalling confidence from sophisticated market participants who typically conduct rigorous fundamental analysis. This institutional backing provides some stability and suggests that the stock’s fundamentals, while challenged, retain appeal for long-term investors.

Long-Term Outlook: Balancing Growth and Risk

While KIMS has demonstrated consistent returns over the last three years and outperformed the BSE500 index annually, its recent financial performance raises concerns about sustainability. The company’s operating profit growth rate of 5.84% annually over five years is modest, and the recent negative quarterly earnings trend suggests challenges in maintaining profitability.

The elevated debt-equity ratio and declining interest coverage ratios highlight increasing financial risk, which investors must weigh against the stock’s relative valuation discount and strong institutional support. The mixed technical signals further underscore the need for cautious optimism.

Investors should monitor upcoming quarterly results closely, particularly for improvements in profitability metrics such as PAT and ROCE, as well as any deleveraging efforts that could improve the debt profile. The stock’s recent price strength and outperformance relative to benchmarks provide some encouragement, but the fundamental challenges remain significant.

Summary of Ratings and Scores

As of 11 February 2026, Krishna Institute of Medical Sciences Ltd holds a Mojo Score of 33.0 with a Mojo Grade of Sell, upgraded from Strong Sell. The financial trend rating has shifted from negative to very negative, reflecting deteriorating profitability and rising leverage. The technical trend has improved from bearish to mildly bearish, indicating some stabilisation in price momentum.

Market capitalisation grade remains at 3, consistent with its mid-cap status in the hospital sector. Despite the upgrade, the overall assessment remains cautious due to the company’s financial challenges and valuation concerns.

Conclusion: A Cautious Upgrade Amidst Mixed Signals

The upgrade of Krishna Institute of Medical Sciences Ltd from Strong Sell to Sell reflects a complex interplay of factors. While the company’s financial performance has worsened, particularly in profitability and leverage, recent price gains and improved technical indicators have tempered the outlook. Investors should remain vigilant, balancing the stock’s relative valuation and institutional backing against ongoing financial headwinds and mixed technical signals.

For those considering exposure to the hospital sector, KIMS offers a nuanced proposition: a stock with strong revenue growth and institutional interest but facing significant profitability and debt challenges. The current Sell rating suggests that while the worst may be behind, the path to recovery remains uncertain and requires close monitoring.

Unlock special upgrade rates for a limited period. Start Saving Now →